A Phase 3 clinical trial has been launched in Brazil to evaluate a candidate vaccine, TV003, developed by NIH scientists, to prevent dengue fever, a mosquito-borne illness. Dengue fever is a common disease in tropical and subtropical regions, with up to 400 million infections annually worldwide. The vaccine aims to elicit antibodies against all four dengue virus serotypes, providing immunity to all strains. The trial will enroll 17,000 healthy individuals aged 2 to 59 years in 13 cities in Brazil, with two-thirds receiving the vaccine and one-third receiving a placebo. The trial will last for five years, with early indications of efficacy expected in less than two years. The goal is to determine if the vaccine can prevent dengue fever and assess its safety. The Butantan Institute is sponsoring the trial.
NIH’s National Institute of Allergy and Infectious Diseases (NIAID) conducts research to study infectious and immune-mediated diseases and develop better treatments. The new trial in Brazil aims to address the significant impact of dengue fever in the country and leverage its strong health infrastructure to test the vaccine candidate. More information about the trial can be found on clinicaltrials.gov with the identifier NCT02406729. NIH is a part of the National Institutes of Health (NIH), which is the primary federal agency for medical research in the United States. For more information about NIH and its programs, visit www.nih.gov.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
